At last, fully scalable, disposable downstream processing

Tarpon Biosystems was formed to improve the efficiency and lower the costs associated with biomanufacturing. Our technology, called BioSMB™, adapts a proven manufacturing technology for use in the biomanufacturing environment. BioSMB™ downstream processing systems use disposable components to enable flexible, multi- product biomanufacturing, all at a significantly reduced cost.

Over the past decade, the production of biopharmaceutical products and in particular the highest growth segment of the entire pharmaceutical industry, monoclonal antibodies therapeutics, has witnessed a dramatic increase in demand. These innovative, expensive products require a sanitary manufacturing process. These drugs require high patient doses and chronic use and are used as therapies for such diseases as autoimmune disease and cancer.

Tarpon Biosystems BioSMB™ technology enables process efficiency

As the industry has matured, tremendous gains have been realized in the first steps of bioprocess manufacturing, producing more product per liter of manufacturing capacity. This growth has resulted in a bottleneck in the portion of the process called purification or downstream processing. Purification is an essential component of nearly every biopharmaceutical manufacturing process and often accounts for 65-70% of the total manufacturing costs. Purification processes – and the supporting buffer tank capacities – are becoming the dominant roadblock in expanding biopharmaceutical manufacturing, not only in terms of process economy, but in many cases also in terms of facility throughput.

Tarpon Biosystems BioSMB™ technology resolves these downstream bottlenecks. BioSMB allows a significant increase in productivity without introducing new media and/or changing the chemistry or selectivity of the process.

Some recent trends in Biomanufacturing:

• Demand for very large scale bioprocesses and to process more product in existing manufacturing space- “facility fit”
• Enhanced use of disposable technology to prevent contamination risks and decrease validation efforts and an increasing need for flexible manufacturing solutions
• Cost consciousness- need to decrease fixed capital as well as operational costs
• Need to reduce the time required to advance new products to clinical trials